ID   K562/AS-3
AC   CVCL_4V84
DR   Wikidata; Q54899405
RX   PubMed=17261498;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; As2O3).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 29-06-23; Version: 14
//
RX   PubMed=17261498; DOI=10.1532/IJH97.05142;
RA   Seo T., Urasaki Y., Ueda T.;
RT   "Establishment of an arsenic trioxide-resistant human leukemia cell
RT   line that shows multidrug resistance.";
RL   Int. J. Hematol. 85:26-31(2007).
//